This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maree, A. O. Articles by Fitzgerald, D. J. Search for Related Content PubMed PubMed Citation Articles by Maree, A. O. Articles by Fitzgerald, D. J. Related Collections Cardiovascular Pharmacology Signal transduction Platelet function inhibitors Acute coronary syndromes Antiplatelets Platelets

(Circulation. 2007;115:2196-2207.)
© 2007 American Heart Association, Inc.

Contemporary Reviews in Cardiovascular Medicine

Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease

Andrew O. Maree, MSc, MD; Desmond J. Fitzgerald, MD

From the Division of Cardiology, Harvard Medical School and Massachusetts General Hospital, Boston, Mass (A.O.M.); and the UCD Conway Institute, University College Dublin, Belfield, Dublin, Ireland (D.J.F.).

Correspondence to Desmond J. Fitzgerald, MD, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland. Email des.fitzgerald@ucd.ie

Key Words: aspirin • myocardial infarction • pharmacokinetics • pharmacology • platelets • thrombosis • clopidogrel

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Humans require rapidly responding, tightly regulated hemostasis because of their closed high-pressure circulatory system. Minor variation in response may predispose to pathological bleeding or thrombosis. In the appropriate setting, pharmacological intervention with antiplatelet therapy stabilizes the atherothrombotic phenotype, though with concomitant hemorrhagic risk. Populations with favorable risk–benefit ratios for acetylsalicylic acid (aspirin) and clopidogrel therapy have nevertheless been defined in major clinical trials. Treatment benefit is established for secondary prevention of cardiovascular and cerebrovascular events, management of acute coronary syndromes, and as an adjunct to percutaneous and surgical revascularization. There is evidence, however, that not all individuals respond comparably to antiplatelet drugs and hence the concept of aspirin and clopidogrel "resistance" has arisen. The term is misleading though because there are many determinants of failure to respond to treatment.

	Clinical Imperative for Consistent Platelet Inhibition

 
Consistent levels of platelet inhibition are required to deliver effective therapy. Adverse consequences of variable response are particularly apparent when antiplatelet drugs are used as an adjunct to coronary revascularization. During percutaneous coronary intervention (PCI), atherosclerotic plaque is invariably disrupted, thrombosis occurs, and endothelial healing is delayed. Intensive periprocedural platelet inhibition minimizes morbidity and mortality, whereas persistence of a prothrombotic environment necessitates chronic antiplatelet therapy. Failure to provide adequate platelet inhibition in all individuals can result in stent thrombosis, myocardial infarction, and death.^1,2 Platelet inhibition with aspirin at the time of coronary artery bypass graft surgery also provides benefit. Yet aggressive therapy with aspirin and clopidogrel combined may increase perioperative bleeding in some cases.³ These contrasting clinical problems underlie the need . . . [Full Text of this Article]

This article has been cited by other articles:

				T. Mueller, B. Dieplinger, W. Poelz, and M. Haltmayer Utility of the PFA-100 Instrument and the Novel Multiplate Analyzer for the Assessment of Aspirin and Clopidogrel Effects on Platelet Function in Patients With Cardiovascular Disease Clinical and Applied Thrombosis/Hemostasis, December 1, 2009; 15(6): 652 - 659. [Abstract] [PDF]

				J. S. Berger, D. L. Bhatt, C. P. Cannon, Z. Chen, L. Jiang, J. B. Jones, S. R. Mehta, M. S. Sabatine, S. R. Steinhubl, E. J. Topol, et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J. Am. Coll. Cardiol., November 17, 2009; 54(21): 1935 - 1945. [Abstract] [Full Text] [PDF]

				D. Shimbo, W. Chaplin, S. Kuruvilla, L. T. Wasson, D. Abraham, and M. M. Burg Hostility and Platelet Reactivity in Individuals Without a History of Cardiovascular Disease Events Psychosom Med, September 1, 2009; 71(7): 741 - 747. [Abstract] [Full Text] [PDF]

				C. Verstuyft, T. Simon, and R. B. Kim Personalized medicine and antiplatelet therapy: ready for prime time? Eur. Heart J., August 2, 2009; 30(16): 1943 - 1963. [Full Text] [PDF]

				A R Muir, M F McMullin, C Patterson, and P P McKeown Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease Heart, August 1, 2009; 95(15): 1225 - 1229. [Abstract] [Full Text] [PDF]

				M. Valgimigli, G. Campo, N. de Cesare, E. Meliga, P. Vranckx, A. Furgieri, D. J. Angiolillo, M. Sabate, M. Hamon, A. Repetto, et al. Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study Circulation, June 30, 2009; 119(25): 3215 - 3222. [Abstract] [Full Text] [PDF]

				M. J. Eisenberg, P. R. Richard, D. Libersan, and K. B. Filion Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents Circulation, March 31, 2009; 119(12): 1634 - 1642. [Abstract] [Full Text] [PDF]

				E. I. Lev Aspirin resistance transient laboratory finding or important clinical entity? J. Am. Coll. Cardiol., February 24, 2009; 53(8): 678 - 680. [Full Text] [PDF]

				J. W. Eikelboom, G. J. Hankey, J. Thom, D. L. Bhatt, P. G. Steg, G. Montalescot, S. C. Johnston, S. R. Steinhubl, K.-H. Mak, J. D. Easton, et al. Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk Circulation, October 21, 2008; 118(17): 1705 - 1712. [Abstract] [Full Text] [PDF]

				A. M. Gori, R. Marcucci, A. Migliorini, R. Valenti, G. Moschi, R. Paniccia, P. Buonamici, G. F. Gensini, R. Vergara, R. Abbate, et al. Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents J. Am. Coll. Cardiol., August 26, 2008; 52(9): 734 - 739. [Abstract] [Full Text] [PDF]

				Y. Yano, T. Ohmori, S. Hoshide, S. Madoiwa, K. Yamamoto, T. Katsuki, T. Mitsuhashi, J. Mimuro, K. Shimada, K. Kario, et al. Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad Eur. Heart J., July 2, 2008; 29(14): 1729 - 1738. [Abstract] [Full Text] [PDF]

				N. Zimmermann, E. Gams, and T. Hohlfeld Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 93 - 108. [Abstract] [Full Text] [PDF]

				M. Fisher and T. Johns Letter by Fisher and Johns Regarding Article, "Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease" Circulation, November 6, 2007; 116(19): e521 - e521. [Full Text] [PDF]

				A. E. Rodriguez, A. O. Maree, J. Mieres, D. Berrocal, L. Grinfeld, C. Fernandez-Pereira, V. Curotto, A. Rodriguez-Granillo, W. O'Neill, and I. F. Palacios Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry Eur. Heart J., September 1, 2007; 28(17): 2118 - 2125. [Abstract] [Full Text] [PDF]

				D. J. Fitzgerald and A. Maree Aspirin and Clopidogrel Resistance Hematology, January 1, 2007; 2007(1): 114 - 120. [Abstract] [Full Text] [PDF]